Literature DB >> 17675621

Safety and utility of uterine artery embolization with CO2 and a gadolinium-based contrast medium.

Hyun S Kim1, Jason Tsai, Ben E Paxton.   

Abstract

The authors evaluated the safety and clinical outcomes of uterine artery embolization (UAE) without the use of conventional iodinated contrast media for symptomatic uterine leiomyomata. Patients underwent UAE with use of CO(2) gas and a gadolinium-based contrast medium. The safety and feasibility of the technique were assessed. Patients were followed up at 24 hours, 1 month, and 6 months after UAE and yearly thereafter. UAE without iodinated contrast medium was attempted in eight patients (mean age, 42.7 years +/- 4.1), and bilateral UAE was successful in all patients. The mean fluoroscopy time was 14.9 minutes. The mean amount of gadolinium-based contrast medium used was 30.6 mL or 0.181 mmol/kg. No major complications were noted. The mean improvement in the symptom severity score was 53.8. The mean reduction in leiomyoma volume was 42%. To date, no repeat interventions have been performed. UAE with CO(2) and a gadolinium-based contrast medium is a viable treatment option for patients with a severe allergy to iodinated contrast media or renal insufficiency.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17675621     DOI: 10.1016/j.jvir.2007.03.014

Source DB:  PubMed          Journal:  J Vasc Interv Radiol        ISSN: 1051-0443            Impact factor:   3.464


  2 in total

Review 1.  Use of carbon dioxide as an intravascular contrast agent: A review of current literature.

Authors:  Fahad Ali; Muhammad Asif Mangi; Hiba Rehman; Edo Kaluski
Journal:  World J Cardiol       Date:  2017-09-26

2.  Quality care guidelines for uterine artery embolisation in women with symptomatic uterine fibroids in Australia and New Zealand: According to the AGREE-II checklist and endorsed by the Interventional Radiology Society of Australasia.

Authors:  Warren Clements; Nicholas Brown; Brendan Buckley; Chris Rogan; Hong Kuan Kok; Eisen Liang
Journal:  J Med Imaging Radiat Oncol       Date:  2022-07-03       Impact factor: 1.667

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.